Acceptability Study of Rapid Screening for Hepatitis B, C, and HIV in Drug Users at Non-traditional Community Sites Using TROD and FibroScan

What this Trial Is About

This research aims to evaluate the acceptability of simultaneous screening for viral Hepatitis B, Hepatitis C, and HIV among drug users in non-conventional care settings. The study involves coordinated monthly screening days where health professionals including hepatologists, addictologists, nurses, and social workers work together to assess and provide appropriate management for each participant. This approach is designed to offer comprehensive screening and care in a supportive environment outside traditional healthcare facilities. The screening process includes several steps patients visiting on screening days receive individualized attention and data collection by the care team. They are offered rapid diagnostic tests TRODs for Hepatitis B, C, and HIV, and a FibroScan to assess liver health. Positive results lead to additional tests like delocalized PCR for Hepatitis C RNA or blood tests for HIV and Hepatitis B serologies. Immediate consultation with a hepatologist follows, with confidential result delivery and discussion of further care options. Prevention advice and vaccination for Hepatitis B may also be provided. Participants engage in routine care procedures, including diagnostic tests and consultations during the screening days. Researchers monitor the number of tests performed, patient attendance, acceptance of consultations, vaccination rates, treatment initiations, and treatment adherence over a period of up to 10 years. This long-term follow-up helps assess the programs impact on managing viral infections among drug users, with ongoing support provided by the healthcare team throughout the study duration.

Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures